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Patients with tuberculosis frequently develop anergy, a state of T-cell hyporesponsiveness in which defective T-cell costimulation
couldbeafactor.ToknowiftheexpressionofT-cellcostimulatorymoleculeswasalteredintuberculosis,weanalyzedtheperipheral
blood T-cell phenotype of 23 Mexican patients with pulmonary tuberculosis. There was severe CD4 (P<. 001) and CD8 (P<. 01)
lymphopenia and upregulation of costimulatory molecule CD30 on CD4 and CD8 T cells (P<. 05); this increase was higher in
relapsing tuberculosis. The main ﬁnding was severe downregulation of the major costimulatory molecule CD28 on both CD8
and CD4 T cells (P<. 001). Depletion of the CD4/CD28 subset, a hitherto undescribed ﬁnding, is relevant because CD4 T cells
constitute the main arm of the cell-mediated antimycobacterial immune response.
1.Introduction
T cells play a central role in the response to mycobacte-
ria. After antigen presentation by accessory cells, CD4 T
lymphocytes are activated to produce IFN-γ, the prototypic
Th1 cytokine that enhances the mycobactericidal capacity
of macrophages [1]. CD8 T cells also contribute pro-
ducing IFN-γ, lysing mycobacteria-infected macrophages,
and killing bacilli through a granule-dependent mechanism
[2]. Despite high immunogenicity of mycobacterial compo-
nents, 17–25% of patients are anergic to tuberculin [3, 4].
Anergy can be reversed with antituberculous chemotherapy,
although in some patients it may persist despite treatment
[4]. Anergy might be related to multiple factors, including
CD4 T-cell lymphopenia [5, 6], poor production of IL-2
and IFN-γ [4], defects in IFN-γ and IL-12 receptors [7, 8],
dysregulation of the cytokine network with predominance of
a Th2 response [9], and increased T cell apoptosis [10]. The
c a u s a lf a c t o r si n v o l v e di ni m p a i r e di m m u n i t yi nt u b e r c u l o s i s
(TB) are largely unknown. Some data suggest a role for
ethnic and genetic factors [4, 11].
The role of T-cell costimulation in the response to
microbes has been well documented [12], although similar
information about Mycobacterium tuberculosis (Mtb) infec-
tion is scanty. In particular, little is known about the status
of the CD28/B7 pathway, which is crucial for activation of
Th1 lymphocytes the main arm of the immune response
against mycobacteria [1, 2]. In vitro studies have shown
thatmycobacteriaupregulatetheexpressionofcostimulatory
molecules by host cells [13], although the opposite has been
also reported [14]. In human TB, B7-1, B7-2 can be seen in
lung granuloma macrophages [15], and by ﬂow cytometry
depletion of the CD8/CD28 subset has been demonstrated
[16].TheimportanceoftheCD28/B7costimulationpathway
is highlighted by a recent study with B7DKO mice that were
highly susceptible to chronic mycobacterial infection, this
susceptibility being due to impaired Th1 T-cell responses
[17].2 Tuberculosis Research and Treatment
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Figure 1: Representative forward by side scatter distribution for enriched lymphocytes used in our ﬂow cytometry analysis is shown (a).
Representative dot plots to show diﬀerences between CD3/CD4 and CD3/CD8 populations of controls (b, c) and tuberculosis patients (d, e).
The main purpose of this study was to determine the
status of T-cell costimulatory molecules in TB. For this, we
carried out a ﬂow cytometry analysis of peripheral blood
T cells in a group of 23 Mexican patients with active
pulmonary TB. We analyzed, together with lineage and
activation markers, costimulatory molecules CD28, CD40L,
CD30, CD30L, and CD27.
2. Study PopulationandMethods
2.1. Study Population. Twenty-three HIV-1 negative patients
with active pulmonary TB were studied. Patients were
admitted to the outpatient clinic of the Hospital de Infec-
tologia, Centro Medico La Raza (IMSS) in Mexico City. The
evolution time since the appearance of clinical symptoms
varied from 2 to 88 months. The diagnosis, established on
clinical and radiological grounds, was conﬁrmed by acid-fast
smears and culture of sputum in all cases. In all patients drug
resistance tests of isolated strains were carried out. Patients
were treated with isoniazid, rifampicin, and ethambutol. As
controls, cells were obtained from 15 HIV negative healthy
individuals of similar ages and sex distribution as the TB
group. Patients and controls gave informed consent to carry
out all studies, including tests for HIV.
2.2. Monoclonal Antibodies. Monoclonal antibodies (mAbs),
unlabeled or labeled with ﬂuorescein isothiocyanate, phy-
coerythrin, or phycoerythrin-Cychrome-5 were obtained.
From Serotec (Raleigh, NC, USA) mAb against CD3 (clone
UCHT1, IgG1), CD45RA (clone F8-11-13, IgG1), CD30L
(clone MB1, IgG2b), CD40L (clone TRAP1.3.6, IgG1),
and CD27 (clone LT27, IgG2a). From Pharmingen (San
Diego CA, USA) mAb against CD4 (clone RPA-T4, IgG1),
CD28 (clone CD28.2, IgG1), CD95 (clone DX2, IgG1), and
CD45RO (clone UCHL1, IgG2b). From Dako Corporation
(Carpinteria CA,USA)weobtainedmAbagainstCD4(clone
MT310, IgG1), CD8 (clone DK25, IgG1), and CD30 (clone
Ber-H2, IgG1). Appropriate isotype control antibodies were
employed.
2.3. Flow Cytometry Assay. Blood samples were obtained
from patients and controls by venipuncture in vacutainer
tubes (Becton Dickinson, San Jose CA, USA) with EDTA
as anticoagulant. All patients had been in chemotherapy for
various lengths of time when the blood sample was obtained.
Peripheral blood mononuclear cells (PBMCs) were isolated
by centrifugation in Histopaque-1077 gradient (Sigma, St
LouisMO,USA).PBMCs(5×105)werestainedwithmAbor
isotype control antibodies for 30 minutes, in the dark at 4◦C,Tuberculosis Research and Treatment 3
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Figure 2: Representative dot plots to illustrate the diﬀerences of CD28+ populations between controls (a, c) and TB patients (b, d).
and washed in PBS with 1% fetal bovine serum and 0.1%
sodium azide. Cells were incubated with appropriate labeled
secondary antibodies for 30min after the primary antibody.
After rinsing, cells were ﬁxed with 1% paraformaldehyde
in PBS. At least 10,000 cells were analyzed in a two-color
FACScan (Becton Dickinson, San Jose CA, USA) operating
with CellQuest software and a 488nm argon laser. The
lymphocyte gate was set following established forward and
side scatter parameters [18]. For each marker, positive
values were set after eliminating with adequate controls
autoﬂuorescenceandthesignalelicitedbytheisotypecontrol
antibody.
3.StatisticalAnalysis
Data were analyzed with a Mann-Whitney nonparametric
test using Graph Pad Prism version 3.02 for Windows,
(Graph Pad Software, San Diego CA, USA).
4. Results andDiscussion
In view of the lack of information about the causal factors
involved in the poor T-cell response frequently found in the
TBpatient,wecarriedthisﬂowcytometrystudywhichaimed
to know the status of T-cell costimulatory molecules. The
main clinical and laboratory data of the 23 patients included
in this study are shown in Table 1. Total white blood cell
counts were performed on all samples using an automated
cell counter and diﬀerential leukocyte counts were done by
Giemsa staining. The normal ranges for WBC are WBC 4–
11 ×103/mm3; lymphocytes 16%–45%; polymorphonuclear
leukocytes 45%–74%; monocytes 4%–10%.
Eleven of the 23 TB patients (47.8%) had relapsing
disease; these patients had completed chemotherapy and
were readmitted with recurrent respiratory symptoms due
to reactivation of lung TB as revealed by chest x-ray and
acid-fast staining and/or culture of sputum. In 16 patients,
multidrug Mtb resistant (MDR) strains were isolated. This
high number of resistant strains is due to the fact that
patients were recruited from a referral infectious disease
hospital. In Mexico, 5.8% of all TB cases are due to
MDR strains [19]. Ten patients were women and 13 were
males, ranging from 29 to 78 years in age. The average
age was 55 ± 14 years and 6 patients were elderly (65
years or more). This age distribution is in keeping with
data showing increased frequency of TB in the geriatric
population [20]. The incidence rate of pulmonary TB in the
general population in Mexico in 1994 was 14.9/100,000, and
in subjects of 65 years or older it was 45.8/100,000 [21].
Since old individuals frequently present variations in T-cell
phenotype [22], in order to have a similar average age as the
TB group, elderly individuals were included in the control
group. The average age of controls was 48 ± 19, the range4 Tuberculosis Research and Treatment
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Figure3:Flowcytometryanalysisofperipheralbloodcellsfrom23patientswithpulmonarytuberculosisand15healthycontrols.Percentage
and absolute numbers of CD4 and CD8 T cells are presented. The expression of CD28 on CD4 and CD8 T cells is also shown. The box plot
represents the median, 25/75 percentile, and extreme values. Asterisks represent statistically signiﬁcant diﬀerences. ∗∗P<. 01, ∗∗∗P<. 001.
from 21 to 81 years and 3 controls were elderly. In Table 2,
clinical and laboratory data of control individuals are shown.
No signiﬁcant diﬀerences between controls and TB patients
were found regarding age, sex, and white blood cell counts.
In Figure 1(a), a representative forward by side scatter
distribution for enriched lymphocytes used in our ﬂow
cytometry analysis is shown. In the same Figure 1 are shown
representative dot plots with the percentages of CD3/CD4
and CD3/CD8 cells from controls (b, c) and TB patients
(d, e). In Table 3, the numeric expression of all ﬂow
cytometry ﬁndings is presented. There was depletion of
T cells with the pan T-cell marker CD3 (P<. 05). Absolute
numbers of lymphocyte subsets were calculated multiplying
the percentage of a determined subset as shown by ﬂow
cytometry by the absolute lymphocyte count obtained with
an automated hematology analyzer. CD4 T-cell counts were
severely diminished in both absolute number and percentage
(P<. 001). CD8 T cells were also diminished but to a
lesser extent (P<. 01, absolute number and percentage).
It is of note that the level of CD4 T-cell depletion in
some patients was comparable to that seen in AIDS patients
[23]. There was no association between age and CD4
or CD8 lymphopenia or between ﬁrst-time and recurrent
TB. The factors involved in T-cell depletion are poorly
known. The recovery of T-cell counts in some patients after
chemotherapy suggests a direct eﬀect of mycobacteria [24];
sequestration of T cells in infected tissues has been also
entertained [25]. Reduction of CD4 and CD8 T cells might
inﬂuence the outcome of infection; these cells play a central
role in antimycobacterial immunity, as shown by depletion
with monoclonal antibodies [26], or by adoptive transfer in
murine models of TB [27]. Similarly, the loss of CD4 T cells
in HIV infection dramatically augments susceptibility to TB
[23]. In a study, decreased CD4 T-cell counts were associated
with severe disease and higher mortality [6]. In our study
it was not possible to evaluate the impact of lymphopenia
on the outcome of the infection, since followup of patients
was insuﬃcient. To obtain information about the activation
and memory status of T cells, we analyzed CD45RA, a
marker of na¨ ıve T-cells, and CD45RO that characterizes
memory/eﬀector T cells [28]. CD45RA was within normal
valueswhileCD8/CD45RO cellswerediminished inabsolute
number (P<. 05). As far as the CD4/CD45RO subset, there
appeared to be a decreased absolute number of these cells
in the TB group compared with healthy controls (controls
486 ± 42; TB 345 ± 39), although this tendency did not
reach statistical signiﬁcance. In contrast, the percentage
of CD4/CD45RO T cells was signiﬁcantly increased (P<
.01) indicating CD4 T cell-activation, an immune response
characteristic of tuberculosis infection [1]. This ﬁnding is
in keeping with a ﬂow cytometry analysis of cells recovered
from tuberculous lungs by bronchoalveolar lavage showing
that the great majority of CD4 T cells were CD45RO+ [29].
Contrary to that reported in the literature [10, 30], CD4Tuberculosis Research and Treatment 5
Table 1: Clinical and laboratory data in patients with tuberculosis.
Patient Age (years) Sex Relapses Duration (months) Strain WBC (mm3) Lymph (%) Mono (%) PMN (%)
01 39 F — 12 R 5500 20 3 77
02 49 F — 12 S 4800 30 3 67
03 49 M
√
24 R 6900 28 1 71
04 44 M
√
22 R 13700 23 2 75
05 47 M — 10 S 5700 24 2 74
06 64 M
√
63 R 6800 32 3 65
07 57 M
√
16 S 4200 32 1 67
08 75 M — 12 R 6700 22 1 77
09 78 M — 22 R 6500 24 5 71
10 30 F
√
36 R 7200 28 2 70
11 61 F
√
55 R 8000 29 5 66
12 29 F
√
12 R 10700 17 1 82
13 58 M
√
12 R 5700 42 1 57
14 58 F — 6 S 6400 30 1 69
15 68 F — 4 S 4100 44 0 56
16 63 M
√
36 R 6700 32 8 60
17 40 F — 18 R 5700 34 17 49
18 71 M
√
88 R 8500 25 6 69
19 54 F — 60 R 5600 45 10 45
20 47 M — 2 S 3600 34 5 61
21 74 M
√
36 R 7100 33 16 51
22 66 F — 9 ND 7200 28 2 70
23 46 M — 12 R 6300 55 7 38
M. tuberculosis strains, resistant (R), susceptible (S), ND, not done. WBC, white blood cells; Lymph, lymphocytes; Mono, monocytes; PMN,
polymorphonuclear leukocytes. Duration refers to the duration of the tuberculosis pulmonary symptoms as stated in the clinical records.
Table 2: Clinical and laboratory data in control individuals.
Age (years) Sex WBC (mm3) Lymph (%) Mono (%) PMN (%)
01 39 F 4750 39 1 60
02 33 M ND ND ND ND
03 34 F 4670 34 7 53
04 21 F 5800 48 2 50
05 64 M 5050 41 7 52
06 61 M 7760 32 7 61
07 74 M 9900 22 10 68
08 81 M 5880 24 8 68
09 31 M 9750 20 0 80
10 63 F 6550 28 5 67
11 22 F 8000 39 0 61
12 23 M 5900 38 1 60
13 56 F 5990 28 5 67
14 51 M 7890 23 6 71
15 68 M 6670 24 9 67
F, female; M, male; ND, not done; WBC, white blood cells; Lymph, lymphocytes; Mono, monocytes; PMN, polymorphonuclear leukocytes.
and CD8 T cells expressing the proapoptosis molecule CD95
were not signiﬁcantly diﬀerent in absolute numbers and
percentage from those of healthy controls.
With respect to T-cell costimulatory molecules, we ana-
lyzed CD28, a member of the immunoglobulin superfamily
[31], CD27, CD30, CD30L, and CD40L, which belong to the
TNFfamily[32].ResultsareshowninTable 3.Nostatistically
signiﬁcant diﬀerences were found between patients and con-
trolsregardingCD27andCD40L.Aninterestingobservation
of this study was the increased expression of CD30 on CD4
and CD8 T cells subsets (percentage P<. 05). CD30L was
increased only in percentage in CD8 T cells (P<. 05). These6 Tuberculosis Research and Treatment
Table 3: Phenotype of peripheral blood T lymphocytes in 23 patients with active pulmonary tuberculosis and in 15 healthy controls.
Marker Controls TB Patients
%# % #
CD3 66 ±4 1600 ± 137 56 ± 5∗ 1263 ± 161∗
CD3/CD4 39 ±82 948 ± 90 24 ± 2∗∗∗ 521 ± 47∗∗∗
CD3/CD8 22 ±2 520 ± 56 14 ± 2∗∗ 286 ± 36∗∗
CD4/CD40L 4 ±13 2 ± 10 11 ± 33 0 ± 7
CD8/CD40L 4 ±32 1 ± 15 12 ± 65 6 ± 25
CD4/CD45RA 17 ±4 212 ± 37 32 ± 5 206 ± 43
CD8/CD45RA 61 ±7 330 ± 48 58 ± 7 265 ± 59
CD4/CD45RO 52 ±5 486 ± 42 73 ± 4∗∗ 345 ± 39
CD8/CD45RO 47 ±5 244 ± 39 45 ± 6 153 ± 29∗
CD4/CD30 1 ± 0.58 ± 46 ± 2∗ 28 ± 12
CD8/CD30 1 ± 0.31 ± 15 ± 2∗ 15 ± 7
CD4/CD30L 6 ±16 0 ± 12 23 ± 89 8 ± 23
CD8/CD30L 3 ±11 7 ± 10 13 ± 3∗ 60 ± 21
CD4/CD28 93 ±2 885 ± 82 48 ± 8∗∗ 268 ± 54∗∗∗
CD8/CD28 51 ±3 325 ± 26 24 ± 6∗∗ 63 ± 14∗∗∗
CD4/CD95 43 ±8 425 ± 86 54 ± 7 298 ± 49
CD8/CD95 49 ± 7 280 ± 51 40 ± 8 155 ± 38
CD4/CD27 42 ± 10 401 ± 107 50 ± 9 275 ± 56
CD8/CD27 32 ± 8 154 ± 40 29 ± 78 1 ± 20
Media absolute cell counts and percentage ± SD of ﬂow cytometry, results. Statistically signiﬁcant diﬀerences between controls and tuberculosis patients were
determined by a Mann-Whitney nonparametric test. ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001.
observationsareinagreementwithstudiesshowingthatMtb
is a potent inducer of CD30 [33]. In tuberculous pleurisy
and lung granulomas, CD30 T cells are abundant [33]a n d
high levels of soluble CD30 are found in sera of TB patients
[9]. Increased soluble CD30 correlates with a Th2 pattern
of cytokine production by T cells, that is permissive for the
mycobacterial infection [9, 34].
Regarding CD28, the best studied costimulatory
molecule, results are shown in Table 3 and Figures 2 and 3,
the latter to show data dispersion. There was marked
depletion of the CD8/CD28 subpopulation which was
highly signiﬁcant in both absolute number (P<. 001)
and percentage (P<. 01); decreased expression of the
costimulatory molecule on CD8 T cells of TB patients has
been reported before [16, 30]. In a study with Ugandan
patients, which were much younger than our patients [30],
depletion of the CD8/CD28 subset was not associated
with lymphopenia and there was increased expression of the
proapoptosismoleculeCD95anddecreasedinterferon-gama
production; another diﬀerence was that CD28 expression on
CD4 T cells was not diminished. These diﬀerences could be
r e l a t e dt oe t h n i cf a c t o r so rt od i ﬀerences in the age of the
patients included in the studies. Downregulation of CD28
on CD8 T cells is interesting in view of the important role
that CD8 T cells play in antimycobacterial immunity [1, 2].
However, the signiﬁcance of CD28 on the activation of CD8
T remains ill deﬁned; a strict CD28 dependence has been
documented [35] while in other studies activation of CD8
was shown to proceed normally in the absence of CD28
costimulation [36]. CD8/CD28 negative T cells diﬀer from
CD8/CD28 positive T cells in their high catalytic activity,
elevated interferon-gamma production, and increased
tendency to apoptosis [37].
The main ﬁnding of this study was the highly reduced
counts of CD4/CD28 T cells (Table 3, Figures 2 and 3);
this was highly signiﬁcant in absolute number (P<. 001)
and percentage (P<. 01). Downregulation of CD28 on
CD4 T cells of TB patients has not been, to our knowledge,
previously reported. This ﬁnding is potentially important
since the interaction of CD28 with its ligand B7 is crucial
to activate T cells [31, 38]. T-cell activation in the absence
of CD28 results in anergy [38], a phenomenon present in
17–25% of TB patients [3, 4]. There are few studies on
the status of the CD28/B7 costimulation pathway in TB.
A study showed that dendritic cells challenged with Mtb
upregulate costimulatory molecules, including B7.1 [13],
although, in mycobacteria-infected macrophages, decreased
expression of B7.1 and B7.2 has been documented [14].
In human TB, B7-1, B7-2, and CD40 are demonstrated
in macrophages inﬁltrating granulomas [15]. Recently, it
was shown that B7DKO mice were very susceptible to
mycobacterial infection due to defective Th1 immunity [17].
Studies with other pathogens support the importance of
CD28 in antimicrobial immunity. CD28 (−/−)m i c ea r e
highly susceptible to Chlamydia trachomatis and Salmonella
typhimurium infection [39, 40].
Regarding clinical data, a history of diabetes, and hyper-
tension had no impact on the T cell phenotype of our TB
patients. No diﬀerences were found between age and CD28
downregulation. We could not obtain enough data to assesTuberculosis Research and Treatment 7
a relationship between extent of disease and CD28 depletion.
However, diﬀerences were found when comparing ﬁrst-time
TB with relapsing infection, a variety of TB characterized
by lack of compliance to chemotherapy, frequent isolation
of MDR strains, and a poor outcome [41, 42]. First, 10
of the 11 patients (90.9%) with relapsing TB had MDR
strains while this was found in 6 of 12 ﬁrst-time TB
patients (50%). A signiﬁcant diﬀerence was found in WBC
counts (relapsing TB, 5675/mm3; ﬁrst-time TB, 7053/mm3;
P<. 05). In addition, in relapsing infection CD4 lymphope-
nia was less pronounced (P<. 05), the percentages and
absolute numbers of CD4/CD27 cells were increased (P<
.05), and the number of CD4/CD30 cells was also increased
(P<. 05). No apparent diﬀerences were found regarding the
expression of CD28 between relapsing and ﬁrst-time TB.
5. Conclusions
In summary, in this descriptive ﬂow cytometry study, we
have observed severe phenotypic abnormalities of T cells in
patients with active pulmonary tuberculosis including severe
depletion of CD4 and CD8 T-cell counts. Importantly, we
observed markedly decreased expression of the major T-
cell costimulatory molecule CD28 on both CD8 and CD4
T cells which together with the marked CD4 lymphopenia
could be causal factors in the inadequate cell-mediated
immune responses that frequently complicate the course of
TB. Further studies are warranted to determine if treatment
inﬂuences the T-cell phenotypic changes described in this
paper.
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